Anaplastic lymphoma kinase Press Release

Title Picture
08/19/2018 - 22:51
China National Drug Administration grants rapid approval of Roches Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Rocheusa's picture
Rocheusa
05/16/2018 - 20:22
Follow-up phase III data showed Roches Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
Rocheusa's picture
Rocheusa
05/16/2018 - 15:22
Follow-Up Phase III Data Showed Genentechs Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
Genentech's picture
Genentech
05/15/2018 - 23:31
Chugais ALK Inhibitor Alecensa Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan
Chugai's picture
Chugai
05/15/2018 - 10:59
Enduring neuroblastoma diagnosis with daughter Leah helped Devon Still find a purpose and passion for life after football
Uplifting Athletes's picture
Uplifting Athletes
02/12/2018 - 08:23
U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizers Third-Generation ALK Inhibitor Lorlatinib
Pfizer's picture
Pfizer
01/31/2018 - 20:59
Further Improving Access to Therapies for Non-Small Cell Lung Cancer
Chugai's picture
Chugai
12/20/2017 - 23:41
European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Rocheusa's picture
Rocheusa
12/20/2017 - 23:29
EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
Chugai's picture
Chugai
11/08/2017 - 05:55
Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
Chugai's picture
Chugai
11/06/2017 - 22:30
FDA approves Roches Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Rocheusa's picture
Rocheusa
11/06/2017 - 11:56
FDA Approves Genentechs Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
Genentech's picture
Genentech
10/16/2017 - 06:06
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
10/13/2017 - 04:56
CHMP recommends EU approval of Roches Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Rocheusa's picture
Rocheusa
09/11/2017 - 07:56
Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
09/06/2017 - 01:04
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Rocheusa's picture
Rocheusa
08/02/2017 - 00:42
FDA Grants Genentechs Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
Genentech's picture
Genentech
06/06/2017 - 02:10
Data of Chugai's Alecensa Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
Chugai's picture
Chugai
06/05/2017 - 04:22
Phase III Study Showed Genentechs Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
Genentech's picture
Genentech
06/05/2017 - 03:33
Phase III study showed Roches Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Rocheusa's picture
Rocheusa
05/11/2017 - 01:58
Results of the J-ALEX Study for Chugai's Alecensa are Published in The Lancet Online
Chugai's picture
Chugai
05/09/2017 - 17:05
Precision Medicine Improves Treatment Outcomes for Some Pancreatic Cancer Patients
UniversityofPittsburgh's picture
UniversityofPit...
04/27/2017 - 04:19
Pfizers Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
04/10/2017 - 03:11
Met Its Primary Endpoint in the ALEX Study
Chugai's picture
Chugai
04/09/2017 - 20:24
Phase III Study Shows Genentechs Alecensa Was Superior to Crizotinib in a Specific Type of Lung Cancer
Genentech's picture
Genentech
04/03/2017 - 00:06
Phase III ALUR study supports the use of Roches Alecensa for people with advanced ALK-positive lung cancer
Rocheusa's picture
Rocheusa
03/29/2017 - 22:36
Phase III study shows Roches Alecensa was superior to crizotinib in a specific type of lung cancer
Rocheusa's picture
Rocheusa
02/27/2017 - 03:45
Chugais ALK Inhibitor Alecensa
Chugai's picture
Chugai
02/21/2017 - 03:28
- Alecensa is Available Now in Japan, the United States and Europe -
Chugai's picture
Chugai
02/21/2017 - 01:16
Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer
Rocheusa's picture
Rocheusa
01/17/2017 - 03:00
AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities
AstraZeneca's picture
AstraZeneca
12/16/2016 - 14:37
CHMP recommends EU conditional approval of Roches Alecensa (alectinib) for people with previously treated ALK-positive NSCLC
Rocheusa's picture
Rocheusa
10/19/2016 - 22:57
Roche delivers good sales growth in the first nine months of 2016
Rocheusa's picture
Rocheusa
10/18/2016 - 12:33
New Drug Targets May Boost Protein Inhibitor, Survival for Lung Cancer Patients, Moffitt Cancer Center Study Shows
Moffitt's picture
Moffitt
10/04/2016 - 03:02
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
Rocheusa's picture
Rocheusa
10/04/2016 - 00:14
Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
Chugai's picture
Chugai
10/02/2016 - 23:57
FDA Grants Breakthrough Therapy Designation for Genentechs Alecensa (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
Genentech's picture
Genentech
08/31/2016 - 06:43
XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
08/03/2016 - 07:12
Agilent Technologies Announces Availability of New Companion Diagnostic in Europe
Agilent's picture
Agilent
07/14/2016 - 05:55
Virginia Cancer Specialists First in the World to Enroll Patient in Cutting-Edge Lung Cancer Clinical Trial
McKesson's picture
McKesson
06/28/2016 - 22:50
ALK Technologies Celebrates a Milestone with the 30th Release of PC*MILER
ALK Technologies's picture
ALK Technologies
06/06/2016 - 04:07
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer
Pfizer's picture
Pfizer
06/03/2016 - 04:19
Cancer Treatment Centers of America at Western Regional Medical Center clinical research director is part of five innovative studies presented this week at ASCO
Cancer Treatment Centers of America's picture
Cancer Treatmen...
05/19/2016 - 07:44
Phase III study of Roches Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer
Rocheusa's picture
Rocheusa
05/17/2016 - 22:58
Phase III Study of Genentechs Alecensa (alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People with a Specific Type of Lung Cancer
Genentech's picture
Genentech
04/17/2016 - 08:51
Memorial Sloan Kettering Researchers Promising Entrectinib Clinical Trial Data Highlighted at American Association for Cancer Research Annual Meeting
MSKCC's picture
MSKCC
12/18/2015 - 03:02
Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca’s overall immuno-oncology strategy
AstraZeneca's picture
AstraZeneca
12/17/2015 - 22:30
Lung cancer found to be genetically different disease in young and older patients
Dana Farber's picture
Dana Farber
12/14/2015 - 12:47
Accelerated Approval in Three Months after Priority Review Designation in the US
Chugai's picture
Chugai
12/11/2015 - 17:07
FDA approves new oral therapy to treat ALK-positive lung cancer
FDA's picture
FDA
12/10/2015 - 23:56
FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
Genentech's picture
Genentech
11/30/2015 - 00:49
Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Boehringer-Ingelheim's picture
Boehringer-Ingelheim
09/09/2015 - 08:53
Chugai’s ALK Inhibitor “Alectinib,” New Drug Application
Chugai's picture
Chugai
09/08/2015 - 09:05
FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
Genentech's picture
Genentech
05/13/2015 - 18:57
Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer
Genentech's picture
Genentech